No Prescription |
 |
 | ||
|
Hansepran Lamprene |
|
| ||
No Prescription » Prescription Drugs 8 » Hansepran Lamprene Clofazimine is an antibiotic which attacks the bacteria that cause leprosy by an unknown mechanism. It is thought to interfere with the production of genetic material (DNA) in the bacteria. Clofazimine also has an anti-inflammatory action to reduce the swelling and pain associated with leprosy.Clofazimine is used in combination with other medications and therapy should be continued for at least two years. Buy Hansepran Lamprene and other Prescription Drugs 8 products online at Medstore. Buy Online at Medstore - Click Here!
About Hansepran Lamprene: Product Type: Prescription Drugs 8 Hansepran ( Lamprene Generic Clofazimine ) Hansepran (Lamprene Generic Clofazimine) Lamprene Generic Clofazimine 100mg 2 x 100 Tablets 100mg 4 x 100 Tablets 100mg 100 Tablets 50mg 100 Tablets 50mg 4 x 100 Tablets 50mg 2 x 100 Tablets Lamprene Generic Clofazimine Hansepran
View more Prescription Drugs 8 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
